13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q1 2023 · Filed February 9, 2023 · Accession 0000950123-23-001275
Total Value
$48.3M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | CRSP | 498,558 | $20.3M | 41.93% |
| 2 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $12.3M | 25.42% |
| 3 | Passage Bio, Inc. | PASG | 4,959,769 | $6.8M | 14.16% |
| 4 | CymaBay Therapeutics, Inc. | 23257D103 | 543,753 | $3.4M | 7.05% |
| 5 | Adverum Biotechnologies, Inc. | 00773U108 | 5,068,233 | $2.9M | 6.08% |
| 6 | Aligos Therapeutics, Inc. | ALGS | 2,320,381 | $2.2M | 4.58% |
| 7 | Minerva Surgical Inc. | 60343F106 | 1,673,700 | $373,905 | 0.77% |